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Abstract
Probody™ therapeutics are recombinant, proteolytically-activated antibody prodrugs, engineered 
to remain inert until activated locally by tumor-associated proteases. Probody therapeutics exploit 
the fundamental dysregulation of extracellular protease activity that exists in tumors relative to 
healthy tissue. Leveraging the ability of a Probody therapeutic to bind its target at the site of 
disease after proteolytic cleavage, we developed a novel method for profiling protease activity in 
living animals. Using NIR optical imaging, we demonstrated that a non-labeled anti-EGFR 
Probody therapeutic can become activated and compete for binding to tumor cells in vivo with a 
labeled anti-EGFR monoclonal antibody. Furthermore, by inhibiting matriptase activity in vivo 
with a blocking-matriptase antibody, we show that the ability of the Probody therapeutic to bind 
EGFR in vivo was dependent on protease activity. These results demonstrate that in vivo imaging 
of Probody therapeutic activation can be used for screening and characterization of protease 
activity in living animals, and provide a method that avoids some of the limitations of prior 
methods. This approach can improve our understanding of the activity of proteases in disease 
models and help to develop efficient strategies for cancer diagnosis and treatment.
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1. Introduction
Proteases have long been associated with cancer invasion and metastasis due to their ability 
to degrade extracellular matrix components and their regulation of cleavage, processing, or 
shedding of cell signaling molecules [1]. The proteolytic tumor micro-environment is 
complex, characterized by structurally and functionally diverse proteases that include the 
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matrix metalloproteinases (MMPs), serine proteases, and others [2,3]. The Pro-body 
technology leverages the upregulation of the activity of these proteases in the tumor 
microenvironment to achieve disease tissue-specific therapeutic activity. Probody 
therapeutics contain a masking peptide fused to the N-terminus of the light chain of the 
antibody through a protease-cleavable linker peptide (Fig. 1). In the intact form, the mask 
physically prevents the Probody therapeutic from binding to the target antigen in healthy 
tissues; however, in the diseased environment, the linker is cleaved and the masking peptide 
is released, resulting in a fully active antibody capable of binding to its target antigen. As 
such, the proteolytically cleavable linker, which contains a substrate sequence recognized by 
one or more proteases, can serve to profile the proteolytic environment of the tumor 
microenvironment.
In order to develop substrates that are efficiently cleaved at sites of disease, a better 
understanding of the regulation of protease activity in tumors is needed. However, dissecting 
how proteases carry out their biological functions in vivo has been challenging, because 
their activities are regulated by redundant mechanisms, including regulation of biosynthesis 
at the transcription and translation levels, localization, activation of zymogens and binding 
of endogenous inhibitors and cofactors. Several methods have been developed to identify the 
presence of proteases and their activity, including activity-based probes [4,5], active site 
antibodies [6–8] and proteomics-based approaches [9]. Here we present a new approach for 
detection of in vivo protease activity, through in vivo optical imaging using Probody 
technology. Optical imaging has become a useful approach in biomedical sciences because it 
is a fast, sensitive, and cost-effective method to track and characterize expression of a target, 
detect enzyme activity and monitor cancer progression or regression and response to 
therapies in living animals. Leveraging the ability of a Probody therapeutic to bind to a 
target at the site of disease in a protease-dependent manner, we developed and applied a new 
technique for non-invasive imaging of protease activity in vivo.
2. Methods
2.1. Probody therapeutic expression, purification and labeling
Probody therapeutics were generated as previously described [10]. In brief, Probody 
therapeutics were expressed in a modified pcDNA3.1 mammalian expression vector (Life 
Technologies) and produced in CHO-S cells (Life Technologies). Probody therapeutics were 
affinity-purified with MabSelect SuRe protein A columns (GE Healthcare) coupled to an 
AKTA FPLC (GE Healthcare). The purity of purified Probody therapeutics was analyzed by 
SDS-PAGE, and their homogeneity was analyzed by size exclusion chromatography with a 
Superdex 200, 10/300 GL column (GE Healthcare).
Antibodies and Probody therapeutics were labeled with a near-infrared fluorescent Alexa 
Fluor® 750 dye (ThermoFisher Scientific, A20111) by incubation for 1 h at room 
temperature. The reaction was stopped with 1 M Tris–HCl buffer, pH 8.5 and labeled 
antibody and Probody therapeutics were separated from free dye using Zeba desalting 
columns (Life Technologies, 87768). Degree of labeling (DOL) was determined with 
NanoDrop spectrophotometer. Antibodies and Probody therapeutics with DOL of 2–3 were 
used in the imaging studies.
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2.2. H292 xenograft model
All animal experiments were approved by our Institutional Animal Care Committee 
(IACUC). Mice were maintained with free access to standard chow and water. NCI-H292 
human lung cancer cells were obtained from the American Type Culture Collection (ATCC). 
They were cultured in RPMI medium supplemented with 10% (v/v) fetal bovine serum 
(FBS). The cells were maintained in a humidified atmosphere of 5% CO2 at 37 °C. For 
H292 xenograft studies, 7- to 9-week-old female athymic nu/nu (Charles River Laboratories) 
mice were inoculated subcutaneously in the right hind flank with 5 × 106 NCI-H292 cells 
(ATCC) suspended 1:1 (v/v) with Matrigel in serum-free medium. Clinical observations, 
body weights, and digital caliper tumor volume measurements were made two times weekly 
once tumors became measureable. Tumor volumes were calculated with the formula (ab2)/2, 
where a is the longer and b is the smaller of two perpendicular diameters.
2.3. In vivo imaging of protease activity using Probody therapeutics and competition 
binding to EGFR
H292 xenograft tumor-bearing mice with tumor volumes of 250–500 mm3 were evenly 
distributed by tumor size into 3 groups with n = 3 per group. The animals were then 
pretreated by an intraperitoneal injection of 10 mg/kg of the anti-EGFR Probody therapeutic. 
Control group mice were intraperitoneally injected with PBS or a 10 mg/kg of cetuximab, an 
anti-EGFR monoclonal antibody. Forty-eight hours after pretreatment all mice were injected 
intraperitoneally with 10 mg/kg of AlexaFluor 750 (AF750)-conjugated cetuximab 
(Cetuximab-AF750).
Spectral fluorescence images of the mice were obtained with an IVIS Spectrum/CT imaging 
system (Caliper Life Sciences, PE) at 48 h and 72 h after Cetuximab-AF750 injection using 
excitation and emission wavelengths of 745 nm and 800 nm, respectively. During the 
procedure, the mice were kept under gaseous anesthesia (5% isofluorane) at 37 °C.
2.4. Protease inhibitor A11 blocking studies with Pb-Tx in vivo imaging
H292 xenograft tumor-bearing mice with tumor volumes of 350–750 mm3 were evenly 
distributed by tumor size into two groups with n = 3 per group. The animals were then pre-
treated by an intraperitoneal injection of 15 mg/kg of A11, a human recombinant antibody 
that recognizes the active form of matriptase over the zymogen form and is a specific 
inhibitor of its activity. The control group mice were intraperitoneally injected with 15 
mg/kg of monoclonal anti-CD20 antibody rituximab. Twenty-four hours after pretreatment 
all mice were injected intraperitoneally with 10 mg/kg of AlexaFluor 750 (AF750)-
conjugated Probody therapeutic, (Pb-Tx-AF750). Spectral fluorescence images of the mice 
were obtained at 24 h and 72 h after Pb-Tx-AF750 injection.
2.5. In vivo imaging data analysis
Bright-field photographs were obtained with each image. The merged bright-field 
photographs and fluorescence images were generated using Living Image software 4.1.3 
(Caliper Life Sciences). Tumor-associated fluorescence intensities were quantified in the 
region of interest (ROI). Identical illumination settings (lamp voltage, filters, f/stop, field of 
views, binning) were used for acquiring all images, and the fluorescence emission within 
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each ROI was determined as the average photons per second per centimeter square per 
steradian (p/s/cm2/sr) in the quantitative analysis. Fluorescent intensities detected in tumors 
were further normalized with their corresponding background signals (tumor-to-background 
ratio, TBR). Data are presented as the mean ± SEM of three individual mice.
2.6. Statistical analysis
All mice used for the in vivo imaging studies were included in the analysis. Mean NIR 
fluorescence signals as represented by tumor to background ratios (TBR) of average radiant 
efficiency with SEM were plotted. 48 h and 72 h TBR values were calculated for one mouse 
in the A11/Pb-Tx-AF750 group by interpolation of linear regression analysis based on 0 h, 
24 h and 96 h TBR data. A two-tailed Student’s t test was performed with Microsoft Excel 
to assess the statistical significance of TBR differences between treated and control groups. 
P values of ≤0.05 were considered statistically significant.
3. Results
3.1. In vivo imaging of Probody therapeutic by use of competitive target binding
A Probody therapeutic is a fully recombinant biotherapeutic comprised of a monoclonal 
antibody whose binding to target antigen is blocked by an extension of the NH2-terminus of 
the light chain, called a masking peptide (Fig. 1a and b). The masking peptide is connected 
to the light chain by a linker containing a substrate for one or more proteases. Upon cleavage 
of the substrate-linker by tumor-associated proteases, the mask is removed, and the activated 
Probody therapeutic binds its target, resulting in tumor-localized activity (Fig. 1c). We 
previously described a novel anti-epidermal growth factor receptor (EGFR)–directed 
Probody therapeutic (Pb-Tx) that is efficacious in mouse xenograft models and contains a 
substrate linker LSGRSDNH cleavable by the tumor-associated serine proteases matriptase 
(MT-SP1) and urokinase plasminogen activator (uPA) and by the cysteine protease legumain 
[10]. To evaluate the kinetics of Pb-Tx activation in the tumor microenvi-ronment of living 
animals, we previously used optical in vivo imaging with Pb-Tx constructs directly labeled 
with Alexa750, and demonstrated that the Probody therapeutic could be detected bound to 
tumors in a protease-dependent manner. However, this direct imaging technique has several 
limitations, including passive accumulation of the labeled Probody therapeutic in the highly 
vascularized tumor compartment due to the enhanced permeability and retention (EPR) 
effect, which can lead to high, non-specific background in the images. To address this 
limitation, we have developed an indirect approach that involves imaging using a labeled 
EGFR antibody, cetuximab, and competing for binding of this agent in vivo using a non-
labeled Pb-Tx. In this way, specific, receptor-mediated binding of the activated Pb-Tx can be 
distinguished from non-specific EPR. Moreover, in contrast to conventional in vivo imaging, 
which requires direct labeling of several compounds, our competitive target binding 
approach uses only a single labeled agent, the EGFR antibody, which minimizes variability 
that is often associated with labeling of multiple testing agents, and eliminates potential 
effects of labeling on compound distribution, circulation half-life or binding.
To evaluate this new approach, we used the H292 EGFR-dependent lung cancer xenograft 
model, due to its high expression of EGFR [11] and our prior experience with in vivo 
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imaging using directly labeled Pb-Tx in this model [10]. In that previous study, significant 
Probody therapeutic activation and binding in the tumor microenvironment was detected 48 
h after administration of labeled Pb-Tx. Therefore, in the current study, 48 h pre-treatment of 
tumor-bearing mice with non-labeled Pb-Tx was used, followed by in vivo imaging with the 
parental anti-EGFR antibody (Ab) conjugated with the near-infrared (NIR) fluorescent dye 
Alexa Fluor® 750 (Ab-AF750) (Fig. 2a). The H292 xenograft mouse model was developed 
by subcutaneous inoculation of 5 × 106 NCI-H292 cells suspended 1:1 (v/v) with Matrigel. 
After tumors reached a volume of 250–500 mm3, animals were pre-treated with 10 mg/kg of 
unlabeled Pb-Tx. In addition, control groups of animals were pre-treated either with PBS or 
10 mg/kg of unlabeled parental anti-EGFR antibody (Ab) to demonstrate the maximal 
detectable dynamic range of antigen-dependent accumulation of the labeled antibody. To 
evaluate the antigen-dependent accumulation of Probody therapeutics, all mice were 
administered Ab-AF750 48 h after pretreatment with cold Probody therapeutics, thus 
enabling the detection of non-occupied EGFR. Spectral fluorescence images of the mice 
obtained with an IVIS Spectrum/CT imaging system at 48 h and 72 h after administration of 
Ab-AF750 demonstrated a lower level of tumor-associated NIR fluorescence in the groups 
pretreated with anti-EGFR Ab or Pb-Tx than in mice pre-treated with PBS (Fig. 2b). Tumor-
to-background ratios (TBR) were calculated based on the average radiant efficiency detected 
at the tumor site and a specified non-tumor area. A significant decrease of TBR was 
demonstrated for mice pre-treated with Probody therapeutics when compared to PBS pre-
treated animals at both the 48 h and 72 h time points (Fig. 2c). These results demonstrate 
that both anti-EGFR antibody and Probody therapeutics can effectively compete for binding 
to tumor EGFR with the labeled anti-EGFR antibody in vivo, as detected by optical imaging. 
Previously, we demonstrated that Pb-Tx does not detectably bind EGFR in the absence of 
protease activity in vitro, and that the binding of directly labeled Pb-Tx to EGFR in vivo in 
this tumor model is dependent of the presence of the protease substrate [10]. Taken together, 
these data suggest that our indirect, in vivo competition binding method can image pro-tease 
activity associated with H292 tumors in vivo.
3.2. Matriptase activity is required for activation of Pb-Tx in H292 xenograft model
To further confirm that binding of Pb-Tx to EGFR in H292 tumors is dependent on protease 
activity, we characterized the protease profile of H292 xenograft tumors. Because Pb-Tx was 
designed to be activated by matriptase, we used an active-site–specific, recombinant human 
antibody for matriptase, called A11, which binds only to the active form of matriptase and 
inhibits its activity [7,12]. A11 was labeled with AlexaFluor 488 (AF7488) and 
immunofluorescence staining was performed on formalin-fixed paraffin-embedded (FFPE) 
H292 xenograft tumor sections. As shown in Fig. 3a, active matriptase is localized to H292 
cancer cells, with a characteristic membranous pattern of staining (Fig. 3a). The presence of 
active matriptase was also qualitatively assessed in vivo using NIR optical imaging. A11 IgG 
labeled with the NIR fluorophore AlexaFluor 750 (A11-AF750) was administered to mice 
bearing H292 xenografts tumors and imaged at excitation and emission wavelengths of 745 
nm and 800 nm, respectively. Significant accumulation of labeled A11 probe as compared to 
non-binding control anti-human CD20 antibody (Rituximab, Ritux-AF-750) was detected at 
the tumor site (Fig. 3b), indicating the presence of active matriptase in H292 xenografts in 
vivo. To test whether matriptase activity is necessary for Pb-Tx binding, we pre-treated 
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H292 xenograft-bearing mice with 15 mg/kg of either unlabeled A11 to inhibit matriptase 
activity or a control antibody (Rituximab) and then performed NIR in vivo imaging with 10 
mg/kg of Pb-Tx directly labeled with AF-750 (Pb-Tx-AF750) after 24 h, 48 h and 72 h (Fig. 
3c). Pb-Tx accumulation in tumors and TBR of average radiant efficiency were calculated 
for each time point. Notably, a significant reduction of tumor-associated NIR fluorescence 
was detected in tumor-bearing mice pretreated with matriptase inhibitory antibody as 
compared to mice pre-treated with non-binding antibody control (Fig. 3d and e). This data 
provides further evidence that matriptase-dependent activation of Pb-Tx results in 
accumulation of Pb-Tx in H292 xenograft tumors.
4. Conclusions
In summary, these results support that in vivo imaging with Probody therapeutics can be a 
powerful tool for detection of pro-tease activity in vivo. Furthermore, the novel in vivo 
competition binding method presented in this work demonstrates the potential for detection 
of protease activity in vivo without the limitations of methods that use directly labeled 
Probody therapeutics. The dependence of Pb-Tx tumor accumulation on protease activity 
was confirmed by reduced tumor target binding of Pb-Tx in the presence of a specific 
protease inhibitor. This conclusion is further supported by previously published data that 
demonstrated that Pb-Tx binding depends on the presence of the protease substrate in the 
Probody therapeutic construct.
It should be noted that the ability to obtain data on protease activity non-invasively and 
longitudinally from the same live animal is an important advantage of the in vivo imaging 
approach, enabling generation of more data points from fewer animals. In addition, the non-
invasive assessment of protease activity in vivo minimizes the possibility of data being 
confounded by changes in protease activity from tissue/cellular damage during tissue 
processing. Taken together, in vivo imaging with Probody therapeutics represents a valuable 
approach for monitoring protease activities in living animals, and enables evaluation of their 
role in development and progression of diseases, such as cancer. This information would be 
very useful for the validation of proteases as therapeutic targets and development of potent 
protease activatable drugs, such as Probody therapeutics.
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Fig. 1. 
Structure and design of Probody therapeutics. (A) A Probody therapeutic is a monoclonal 
antibody that contains a light chain extension consisting of a masking peptide (cyan) that 
blocks the antigen-binding site (yellow), and a protease-specific substrate-containing linker 
(orange). (B) In the absence of active protease, the Probody therapeutic is functionally 
masked and cannot effectively interact with target. (C) In the presence of the targeted active 
protease (green), the linker is cleaved, the masking peptide disassociates, and the Probody 
therapeutic becomes competent to bind to its target.
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Fig. 2. 
In vivo imaging of Pb-Tx EFGR binding in an H292 xenograft model. (A) Schematic of the 
in vivo optical imaging method. Imaging was performed at 48 and 72 h following injection 
of cetuximab-AF750 into H292 tumor-bearing mice pretreated with PBS or a 10 mg/kg 
blocking dose of cetuximab or Pb-Tx. (B) Representative images of mice (n = 3) from each 
treatment group at 48 h. (C) Comparison of mean tumor-to-background ratios (TBR) based 
on average radiant efficiency values from cetuximab-AF750 in each group. Each bar 
represents mean TBR ± SEM; n = 3 for each group. *P < 0.05, **P < 0.01.
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Fig. 3. 
Imaging of protease activity in an H292 xenograft model. (A) Immunofluorescence staining 
of matriptase activity using A11 active site-specific antibody in H292 xenograft tumor 
sections. A11 antibody staining is in green and nuclei are stained with DAPI (blue). Scale 
bar, 100 μm. (B) NIR optical imaging of A11-AF750 antibody accumulation in an H292 
xenograft tumor model (right mouse). Rituximab-AF750 antibody was used as a negative, 
non-binding antibody control (left mouse). The images shown are representative of n = 3 
mice/xenograft. (C) Schematic of the in vivo optical imaging study of Pb-Tx binding to 
tumor EGFR in the presence of matriptase inhibitor. Imaging was performed 24 h, 48 h and 
72 h after injection of 10 mg/kg Pb-Tx-AF750 into H292 tumor-bearing mice pretreated 
with 15 mg/kg of either unlabeled A11 or a control antibody (Rituximab). (D) 
Representative images of mice (n = 3) from each treatment group at 48 h. (E) NIR optical 
imaging of Pb-Tx in H292 xenograft tumor bearing mice pre-treated with rituximab or the 
inhibitory matriptase matriptase antibody A11, followed by administration of labeled Pb-Tx-
AF750. The TBR determined for both groups of mice (n = 3) demonstrate decrease of NIR 
Wong et al. Page 10
Biochimie. Author manuscript; available in PMC 2017 November 30.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
fluorescence in tumors of mice pretreated with matriptase inhibitor A11. *P < 0.05, **P < 
0.01.
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